Ethylene Chlorohydrin (2-Chloroethanol) Residue Analysis for Ethylene Oxide Sterilized Medical Devic

Ethylene chlorohydrin (2-chloroethanol, ECH) residue analysis is a critical quality and safety control for medical devices sterilized with ethylene oxide (EO), ensuring compliance with ISO 10993-7 and GB/T 16886.7 residual limits before product release. This article provides a professional technical overview of ECH formation, sample types, testing items, analytical methods such as headspace gas chromatography, and practical guidance for manufacturers seeking reliable residue evaluation at accredited third-party laboratories.

Technical Overview

Ethylene chlorohydrin (2-chloroethanol, ECH, CAS 107-07-3) is a toxic reaction byproduct generated during ethylene oxide (EO, CAS 75-21-8) sterilization of medical devices. When EO reacts with chloride-containing species, such as residual physiological fluids, saline contaminants, moisture, or chloride additives in polymeric materials like plasticized PVC, under the humid and elevated-temperature conditions of a typical EO sterilization cycle, ECH is formed as a stable and water-soluble compound. Unlike EO, which dissipates relatively quickly during aeration, ECH is more persistent in device materials and can even continue to form in situ after sterilization if residual EO and chloride sources remain present.

From a toxicological perspective, ECH exhibits acute toxicity affecting the central nervous system, liver, and kidneys, and it is a significant irritant upon contact with skin, mucous membranes, and blood-contacting surfaces. Because of this hazard profile, international biocompatibility standards strictly regulate ECH residues alongside EO and ethylene glycol (EG) residues. ISO 10993-7 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals) and its Chinese counterpart GB/T 16886.7 establish tolerable exposure limits based on device contact duration and contact type. For devices with limited patient contact (24 hours or less), the commonly cited limits are 4 mg EO per device and 38 mg ECH per device, while prolonged-contact and permanent-contact devices are subject to more restrictive cumulative and daily-exposure limits defined in the standard.

Residue analysis therefore serves as an essential element of the biological safety evaluation required for regulatory registration, product release, and sterilization process control. Manufacturers of EO-sterilized devices typically engage accredited third-party laboratories to perform quantitative ECH determination in accordance with ISO 10993-7, supported by ISO 10993-12 for sample preparation and ISO 10993-18 for chemical characterization principles.

Testing Samples

Any medical device or component that undergoes EO sterilization and contacts patients may require ECH residue evaluation. Samples should be collected from representative sterilized production lots and shipped sealed in airtight containers with minimal headspace to prevent loss of volatile residues during transport.

Single-Use Delivery and Administration Devices

This category includes sterile syringes, infusion sets, blood transfusion sets, intravenous catheters, injection needles with polymeric hubs, stopcocks, and fluid administration tubing. These devices frequently use PVC and polyurethane materials that can retain and generate ECH, and they represent the largest volume of routine ECH residue testing.

Blood-Contacting and Extracorporeal Devices

Hemodialyzers, hollow-fiber oxygenators, blood filters, extracorporeal circulation tubing, and cardiopulmonary bypass components warrant particular attention. Direct and prolonged blood contact, combined with large surface areas and chloride-rich clinical use environments, makes these devices a high-priority group for both EO and ECH residue monitoring.

Implants and Long-Term Contact Devices

Urinary catheters, central venous catheters, shunts, sutures, surgical meshes, and drug-device combination components fall under prolonged or permanent contact categories. These devices are evaluated against the most stringent cumulative exposure limits, and ECH data must be generated with appropriately sensitive analytical methods.

Wound Care, Dressings, and Procedure Kits

Gauze dressings, foam and alginate wound dressings, transparent adhesive films, surgical drapes, gowns, and complete procedural kits assembled and sterilized as single units are routinely tested. Because dressings contact compromised tissue directly, residue control is especially important.

Respiratory and Anesthesia Consumables

Endotracheal tubes, tracheostomy tubes, breathing circuits, anesthesia masks, and heat-moisture exchangers constitute another significant sample group, as EO sterilization is widely used for these heat- and moisture-sensitive polymer products.

Testing Items

The core testing item is the quantitative determination of 2-chloroethanol residue, expressed as milligrams per device, micrograms per gram of material, or micrograms per square centimeter of contact surface. Comprehensive residue studies typically include the following elements:

• Ethylene chlorohydrin (2-chloroethanol, ECH) residual content in the finished sterilized device
• Ethylene oxide (EO) residual content, determined simultaneously or in parallel, together with the total EO plus ECH evaluation required by ISO 10993-7
• Ethylene glycol (EG) residual content, where relevant, to complete the byproduct profile of EO sterilization
• Simulated-use extraction results reflecting clinical exposure scenarios for patient-contact assessment
• Exhaustive extraction results for worst-case total residual burden characterization
• Residue dissipation and aeration behavior studies, including residue-versus-time curves to establish validated degassing and release time points
• Comparative residue data supporting material selection, design changes, sterilization cycle optimization, and shelf-life stability programs

Testing Methods

ECH analysis is performed by gas chromatography, with headspace sampling as the preferred introduction technique because it provides clean extracts, good sensitivity, and compatibility with aqueous extraction media. The general analytical workflow proceeds as follows.

Sample preparation: Following the principles of ISO 10993-12, devices are prepared using either simulated-use extraction, in which the patient-contacting portion is extracted in purified water at approximately 37 °C for a clinically relevant period such as one hour, or exhaustive extraction, in which repeated extractions continue until the residue recovered in a subsequent extraction falls below a defined fraction of the first. Small devices may be extracted whole, while large devices are sectioned so that the patient-contacting components are evaluated representatively.

Headspace gas chromatography with flame ionization detection (HS-GC-FID): Extracts are sealed in headspace vials and equilibrated at an elevated temperature, typically in the range of 80 °C to 90 °C for 30 to 45 minutes, allowing ECH to partition into the vapor phase. The headspace sample is then injected onto a capillary GC column of suitable polarity, and quantitation is performed against a multi-point calibration curve prepared with a certified 2-chloroethanol reference standard. This approach is robust, cost-effective, and widely accepted for routine release testing.

Gas chromatography with mass spectrometric detection (GC-MS): Where enhanced specificity is needed, for example to confirm identity in complex extracts or to resolve coeluting interferences from plasticizers and additives, GC-MS in selected ion monitoring mode is employed. The characteristic fragmentation pattern of ECH, including the chlorine isotope signature of the molecular ion, provides confident identification alongside accurate quantitation at low levels.

Method validation and quality control: In line with ISO 10993-18 expectations and established analytical validation practice, methods are validated for specificity, linearity, range, accuracy, precision, limit of detection, and limit of quantitation. Typical performance criteria include calibration linearity with a coefficient of determination of 0.995 or better, spike recoveries within approximately 85 to 115 percent, and precision with relative standard deviations below 10 percent. Each analytical batch incorporates reagent blanks, calibration verification standards, duplicate determinations, and matrix spike recovery checks to demonstrate ongoing control.

Data evaluation: Reported ECH concentrations are converted to milligrams per device, averaged across the required number of replicate devices, and compared against the applicable ISO 10993-7 or GB/T 16886.7 limits for the device contact category. Results are interpreted together with EO residue data, since the standard addresses combined exposure from sterilization residuals.

Applications

ECH residue analysis supports multiple stages of the medical device lifecycle:

• Product release testing and lot acceptance for EO-sterilized devices prior to distribution
• Sterilization cycle development and validation, including aeration cycle design and the establishment of validated degassing dwell times
• Regulatory submissions and conformity assessment, providing residual data required in registration dossiers for national market approvals
• Material and design change evaluation, comparing residue behavior when polymers, suppliers, adhesives, or packaging configurations are modified
• Shelf-life and stability studies, monitoring residue levels across real-time and accelerated aging to confirm continued compliance over the claimed expiry period
• Root-cause investigation of out-of-specification results, supporting corrective actions in sterilization loading, humidity control, and aeration parameters
• Supplier control and incoming inspection programs for contract-sterilized components and subcontracted finished goods

FAQ

Why can ECH residues be high even when EO residues are compliant?

ECH is more persistent than EO and dissipates much more slowly during aeration. In addition, residual EO remaining in the device can continue to react with chloride-containing moisture or additives during storage, generating additional ECH after sterilization. For this reason, both parameters must be monitored over time, and aeration studies should extend long enough to characterize ECH behavior, not only EO decline.

What is the acceptance limit for ECH residues?

Under ISO 10993-7 and GB/T 16886.7, devices with limited patient contact of 24 hours or less are subject to a tolerable ECH exposure of 38 mg per device. Devices with prolonged contact between 24 hours and 30 days, and permanent contact beyond 30 days, are governed by more restrictive cumulative and daily-exposure limits specified in the standard, and the applicable category must be determined for each device before evaluation.

How should samples be collected and shipped for testing?

Samples should be taken directly from sterilized production lots in their original breathable packaging, then transferred into airtight containers such as sealed glass jars or laminated foil bags with minimal headspace. Samples should be kept cool, protected from heat sources, and shipped promptly with a documented chain of custody, since improper handling can cause volatilization losses and underestimation of true residue levels.

Which detector is better for ECH analysis, FID or MS?

HS-GC-FID is fully adequate for routine quantitation in well-characterized matrices and offers excellent repeatability and throughput. GC-MS adds a higher degree of specificity and is recommended when extracts are complex, when interferences are suspected, or when confirmatory identification is required for regulatory or investigative purposes. Many laboratories use FID for routine screening and MS for confirmation.

How many devices are required for a residue test?

ISO 10993-7 requires residue data from an appropriate number of replicate devices to establish an average residue level, commonly a minimum of three to five devices per time point for routine release testing, and larger sample sets for validation and dissipation studies. The exact quantity depends on device size, extraction approach, and the study design agreed upon with the testing laboratory.

What is a typical turnaround time for ECH residue testing?

Standard quantitative determination of ECH, together with EO, is generally completed within approximately five to ten working days after sample receipt for routine testing. Studies involving aeration profiling across multiple time points, exhaustive extraction, or method feasibility work require longer timelines that should be planned during study design.

How can manufacturers reduce ECH residues?

Effective mitigation strategies include optimizing aeration time, temperature, and airflow; reducing chloride and moisture contamination in components before sterilization; selecting lower-absorbing materials; adjusting sterilizer load density and packaging configuration to improve EO removal; and validating a post-sterilization quarantine period supported by residue dissipation data. Process changes should always be confirmed through retesting against the applicable ISO 10993-7 limits.